RudaCure Inc. (CEO Yongho Kim), a 生物风投企业 specializing in pain 药物开发, has been selected as a newly certified '2025 Hi-首尔 Enterprise' by the 首尔特别市 and 首尔产业振兴院 (SBA).
The Hi-首尔 Enterprise certification is a program where 首尔特别市 comprehensively evaluates growth potential, profitability, and global capabilities to select and support promising SMEs in the region. Through this certification, RudaCure has officially been recognized for its 药物开发 technology and business achievements.
In 2024, the average revenue of Hi-首尔 certified companies reached KRW 14.5 billion, with approximately 50% of certified companies expanding into 127 countries, generating annual exports of KRW 3.5 trillion. Currently, a total of 1,259 companies hold this certification, and certified companies enjoy various benefits including preferential selection for SBA-operated programs, marketing and overseas expansion support, and tax and financial advantages.
RudaCure's 干眼症治疗药 RCI001 has recently obtained 美国 FDA Phase 2 临床试验 IND approval, signaling the beginning of the company's advancement into the 全球市场. These results have validated the company's potential and capabilities, demonstrating synergy with the Hi-首尔 Enterprise certification and establishing a strong foundation for growth.
CEO Yongho Kim of RudaCure stated, "The Hi-首尔 Enterprise certification is meaningful as official recognition of RudaCure's innovative technology and growth potential in 新药开发. We will leverage this momentum to secure 全球竞争力 and lead the 疼痛治疗 market through the development of innovative treatments."